• Performs a 20-gene panel to identify activated B-cell and germinal center B-cell subtypes of diffuse large B-cell lymphomas using the NanoString platform under CLIA conditions in formalin-fixed paraffin-embedded samples.
• Includes sufficient basic consultation with a subject matter expert.

Process

• Perform messenger RNA isolation and expression analysis specific to a 20-gene panel on formalin-fixed paraffin-embedded patient samples using the NanoString platform.
  • This assay has been validated for clinical samples and allows for the identification of activated B-cell and germinal center B-cell subtypes of diffuse large B-cell lymphomas to enable assignment to a therapeutic regimen.
• Isolate total RNA from sections of formalin-fixed paraffin-embedded material with a minimum requirement of 62.5 ng to proceed with the assay.
• Perform all assays with internal negative and positive control RNAs, in addition to both activated B-cell and germinal center B-cell control RNAs.
• Generate a mRNA expression profile of each sample and control using a custom panel of capture probes and the NanoString lymphoma subtyping test.
• Classify samples as either activated B-cell or germinal center B-cell subtypes using an established predictor algorithm.

All operations will be performed in a CLIA environment, and the CLIA Molecular Diagnostics Laboratory will provide a final report with the results with interpretations and ‌conclusions. 

Find more details about the assignment to a therapeutic regimen in our scientific publication.